$30.80
Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript
BofA Adjusts Price Target on Alamar Biosciences to $31 From $30
Overview
52-week range
$19
$39
61% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
+1.3%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.22 | — | — | — | — | financials |
| Fri May 8, 2026 | Mar/2026 | $-1.74 | — | — | — | +1.3% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-0.62 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-0.68 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | $29M | $26M | — | $16M | $13M |
| Cost of revenue | $12M | $12M | — | $8M | $7M |
| Gross profit | $18M | $14M | — | $9M | $6M |
| Operating income | $-14M | $-12M | — | $-8M | $-9M |
| Net income | $-13M | $-21M | — | $-7M | $-8M |
| EPS (diluted) | $-0.22 | $-1.74 | — | $-0.62 | $-0.68 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $133M | $65M | $30M | — | — |
| Inventory | $45M | $40M | $38M | — | — |
| Total current assets | $331M | $141M | $95M | — | — |
| Total assets | $391M | $186M | $140M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $78M | $130M | $64M | — | — |
| Total equity | $313M | $-178M | $-159M | $-147M | $-140M |
Implied volatility — last 90 days
No IV snapshots yet for ALMR.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.